Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02449031 · ClinicalTrials.gov registry record
Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
A clinical trial, sponsored by Mylan.
- Completed
- Registry status
- 409
- Enrollment target
NCT02449031: Completed study, sponsored by Mylan.
NCT02449031 is a clinical trial that has completed, run by Mylan. The registered enrollment target is 409 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02449031 has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- 409 participants
- Enrollment target
Study Summary
This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.
Interventions
- DRUG TOBI® PODHALER®
- DRUG TOBI®
- DRUG Bethkis®
- DRUG Cayston®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2015-05-05 |
| Est. Completion | 2021-12-31 |
What the finished NCT02449031 record still lists
NCT02449031 is an observational study that tracks outcomes without assigning an intervention. The registered 409 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 4 interventions - of which TOBI® PODHALER® is the first listed.
NCT02449031 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02449031 about?
NCT02449031 is a clinical study titled "Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs". This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment wit...
What is the current status of trial NCT02449031?
This trial is currently completed. The enrollment target is 409 participants. The study started on 2015-05-05. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02449031?
The interventions under investigation include: TOBI® PODHALER® (DRUG), TOBI® (DRUG), Bethkis® (DRUG), Cayston® (DRUG).
Who is sponsoring clinical trial NCT02449031?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717334 · 409 participants
A Study of Lung Cancer Screening in People With Unexplained Weight Loss
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI